The loss of correlation between aspirin esterase activity and metabolic variables in T2DM may reflect pathophysiological changes affecting aspirin pharmacokinetics and effectiveness.
Answers are grounded in this paper and cite their sources.
May question uniform aspirin metabolism in T2DM; leaves open pharmacokinetic effects on efficacy, needing prospective study.
BACKGROUND: Aspirin esterase (AE) activity can account for part of aspirin pharmacokinetics in the circulation, possibly being associated with the impairment of aspirin effectiveness as an inhibitor of platelet aggregation. AIMS: The study was aimed at investigating the correlations of serum AE activity with cholinesterase (ChE) and metabolic variables in healthy subjects in comparison to subjects with type 2 diabetes mellitus (T2DM). METHODS: In cardiovascular disease-free T2DM subjects and healthy controls, the AE activity levels and/or the correlation patterns between AE and the other variables were analyzed. RESULTS: Neither AE nor ChE activities were higher in the subjects with T2DM. Serum AE activity strongly correlated with ChE as well as glucose/lipids variables such as total cholesterol and triglyceride in healthy subjects, while the correlations between AE and glucose/lipids variables were not present in T2DM subjects. CONCLUSIONS: These data may reflect the pathophysiological changes between healthy and T2DM subjects. Our data may thus provide the basis for future studies to unravel the mechanisms.
No takes yet. Share an insight, caveat, or question.
Kotani et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: